Comprehensive Notes on Hypersensitivity Types I–IV (NP Perspective)

Type I Hypersensitivity (IgE-Mediated)

  • Definition and scope
    • IgE-mediated allergic response involving mast cell and basophil activation with rapid onset
    • Classic features: anaphylaxis, hives, asthma, allergic rhinitis, food allergies
  • Key mediators and players
    • Antibody: IgEIgE{
    • Effector cells: mast cells and basophils
    • Primary mediators released: histamine, leukotrienes, prostaglandins; other inflammatory mediators contribute to symptoms
    • Mediator targets include smooth muscle, vascular endothelium, mucous glands
  • Mechanism (pathophysiology)
    • Allergen exposure leads to sensitization and production of IgEIgE against the allergen
    • IgEIgE binds to FcεRI receptors on mast cells and basophils
    • Re-exposure causes cross-linking of surface-bound IgEIgE, triggering degranulation
    • Resulting clinical signs: bronchoconstriction, vasodilation, increased vascular permeability, mucous production
    • Note: signs are due to chemical mediators, not direct tissue destruction
  • Diagnosis considerations (in the course context)
    • Skin testing (skin prick test): introducing suspected allergens into the skin via needle
    • Serum IgE levels: elevated IgEIgE supports allergic response
    • RAST / specific IgE testing (serum): detects allergen-specific IgEIgE antibodies
    • Emphasis in course: do not diagnose clinically in this course; understanding pathophysiology informs signs, symptoms, and treatment
  • Treatments and management
    • Allergen avoidance: first-line, when allergen is known
    • Antihistamines: block histamine receptors to reduce symptoms
    • Corticosteroids: reduce inflammation and immune response; available in various routes (systemic, topical, inhaled)
    • Epinephrine: lifesaving for anaphylaxis; prompt administration when needed (lifespan safety for patients with known severe allergies; EpiPen availability)
    • Desensitization immunotherapy (allergy shots): gradual exposure to build tolerance; may involve allergist referral
    • Immunotherapy notes: may include allergen-specific desensitization schedules; not always within primary care scope
  • Practical and clinical implications
    • Education: patient education on avoidance strategies and recognition of early symptoms
    • Multimodal treatment: often combination of avoidance, pharmacotherapy, and emergency preparedness
    • Implication for primary care: recognize signs of potential anaphylaxis; develop action plans; coordinate with specialists when needed
  • Examples and scenarios mentioned
    • Anaphylaxis (life-threatening systemic reaction)
    • Bee sting reactions, peanut and other food allergies
    • Allergic rhinitis and asthma presentations common in primary care settings
  • Connections to broader course themes
    • Pathophysiology informs treatment selection: histamine-driven symptoms explain why antihistamines are helpful
    • Ties to pharmacology: understanding receptor targets (H1 receptors, etc.) guides drug choices
  • Quick reference notes (LaTeX-friendly)
    • Onset: rapid after exposure; emergency management critical
    • Pathway: IgE<br/>ightarrowextmastcelldegranulation<br/>ightarrowextmediatorrelease<br/>ightarrowextallergicsymptomsIgE <br /> ightarrow ext{mast cell degranulation} <br /> ightarrow ext{mediator release} <br /> ightarrow ext{allergic symptoms}
    • EpiPen dose and route (epinephrine) are lifesaving during anaphylaxis

Type II Hyper­sensitivity (Cytotoxic)

  • Definition and scope
    • Antibody-mediated cytotoxic reactions where antibodies target antigens on the surface of host cells
    • Major mediators: IgG and IgM
  • Mechanism and pathways
    • Antibodies bind to surface antigens on cells (e.g., red blood cells, thyroid cells)
    • Complement activation via the classical pathway ((C1)–(C9)); formation of the membrane attack complex (MAC)
    • MAC composition: C<em>5b,C</em>6,C<em>7,C</em>8,C9C<em>5b, C</em>6, C<em>7, C</em>8, C_9, leading to cell lysis
    • Antibody-dependent cellular cytotoxicity (ADCC): NK cells recognize Fc regions of bound antibodies via Fc receptors and release cytotoxic granules
    • Opsonization: Fc receptors on macrophages promote phagocytosis of antibody-coated cells
  • Typical clinical outcomes
    • Cell destruction (lysis) or impaired cell function due to antibody binding
    • Inflammation from complement activation
  • Examples discussed
    • Autoimmune hemolytic anemia (AIHA): IgM or IgG antibodies against red cell antigens
    • Graves’ disease: autoantibodies targeting the TSH receptor (TSI) causing thyroid overactivity (see Type II Graves section)
    • Others mentioned: Goodpasture’s disease, myasthenia gravis, hemolytic disease of the newborn
  • Diagnostic approaches
    • Direct Coombs test: detects antibodies bound to red blood cells
    • Indirect Coombs test: detects free antibodies in serum (prenatal testing, transfusion compatibility)
  • Clinical features and signs
    • Anemia-related signs: fatigue, pallor, tachycardia, dyspnea
    • Jaundice may occur due to increased bilirubin from RBC breakdown in AIHA
    • Splenomegaly from increased RBC destruction
  • Treatments and management
    • Corticosteroids as a first-line anti-inflammatory and immunosuppressive strategy
    • Immunosuppressants for steroid-resistant cases or relapses
    • Intravenous immunoglobulin (IVIG): competes with autoantibodies to reduce Fc receptor–mediated clearance
    • Blood transfusions: possible but require careful cross-matching due to autoantibodies; risk of enhancing hemolysis
    • Splenectomy: considered for refractory cases due to splenic RBC destruction
  • Graves’ disease specifics within Type II context
    • Autoantibodies (TSI) mimic TSH and stimulate excessive thyroid hormone production
    • Thyroid tissue not destroyed; hyperfunction rather than cytotoxic destruction
    • Involvement of T helper cells (Th2) aiding B cell activation and autoantibody production; cytokines (e.g., IL-4, IL-10) sustain the autoimmune response
    • Ocular involvement: exophthalmos due to orbital fibroblast and T cell infiltration; other eye symptoms linked to inflammatory changes
  • Diagnostic and treatment caveats
    • Diagnostic confirmation requires broader tests (thyroid function tests, antibodies for Graves’); patient management includes addressing both hyperthyroidism and autoimmune activity
    • First-line antithyroid medications: methimazole and propylthiouracil (PTU)
    • Symptom control: beta-blockers for tachycardia, tremor, anxiety
    • Definitive therapies if needed: radioactive iodine therapy or thyroidectomy (risk of hypothyroidism later)
    • Corticosteroids for inflammatory manifestations like exophthalmos
  • Key clinical reasoning notes
    • Distinguish Type II vs Type III by site of antibody action: surface of cells (Type II) vs circulating immune complexes (Type III)
    • Recognize overlap: lupus shows Type II hematologic components (anemia, leukopenia, thrombocytopenia) alongside Type III systemic features
  • LaTeX-friendly quick references
    • Autoantibodies: IgG,IgMIgG, IgM; target on cell surface; complement involvement via the classical pathway: C<em>1→C</em>9C<em>1\rightarrow C</em>9
    • TSI: thyroid-stimulating immunoglobulins; receptor binding on thyroid cells; excessive thyroid hormone production
    • Graves’ eye manifestations: exophthalmos via orbital fibroblasts and T cells

Type III Hyper­sensitivity (Immune Complex-Mediated)

  • Definition and scope
    • Immune complex–mediated injury from circulating antigen–antibody complexes that deposit in tissues and activate complement
    • Commonly involves multi-system diseases such as lupus and post-streptococcal glomerulonephritis (PSGN)
  • Mechanism
    • Antigen–antibody complexes (usually IgGIgG or IgMIgM) form in circulation
    • Complexes deposit in tissues (kidneys, joints, skin, blood vessels, lungs, etc.)
    • Complement activation (classic pathway) leads to inflammation and neutrophil recruitment
    • Neutrophils attempt phagocytosis of deposited complexes but fail to clear them efficiently, causing tissue injury
  • Typical sites of deposition and related clinical manifestations
    • Kidneys: glomerulonephritis with hematuria, possible renal failure
    • Joints: arthritis (joint swelling and pain)
    • Skin: rash, purpura, serum sickness–like reactions
    • Blood vessels: vasculitis
    • Lungs: alveolitis, pneumonitis
  • Examples highlighted in the session
    • Systemic lupus erythematosus (SLE)
    • Post-streptococcal glomerulonephritis (PSGN)
    • Serum sickness
    • Arthus reaction (local immune complex–mediated reaction)
  • Diagnostic considerations
    • Immunologic testing for lupus (e.g., ANA, anti-dsDNA, anti-Smith) plus complement levels (C3, C4 can be decreased during active disease)
    • Kidney function tests, urinalysis for glomerulonephritis
    • Clinical correlation with multi-system involvement
  • Treatment and management principles
    • Anti-inflammatory and immunosuppressive strategies (NSAIDs for mild inflammation; corticosteroids for broader control; immunosuppressants if needed)
    • Antimalarials (e.g., hydroxychloroquine) for systemic autoimmune processes like lupus
    • Biologic therapies in selected cases
    • Sun protection and lifestyle measures in lupus due to photosensitivity and multi-system involvement
  • Lupus as a case study for Type III with Type II overlap
    • Lupus features predominantly Type III (immune complex deposition) with a Type II hematologic overlap (autoantibodies against blood cells) in some patients
    • The extensive table from the session illustrates the broad organ involvement and how different systems manifest based on the site of immune complex deposition
  • Practical NP implications
    • Multi-disciplinary management is common (nephrology, rheumatology, cardiology, dermatology, etc.) depending on organ involvement
    • Avoid memorizing a single “lupus” signature; integrate clinical presentation across systems
    • Emphasis on prevention of infection and management of inflammatory burden
  • LaTeX-notes for quick reference
    • Immune complexes: extantigen+extIgG/IgM<br/>ightarrowextimmunecomplexext{antigen} + ext{IgG/IgM} <br /> ightarrow ext{immune complex}
    • Complement: C<em>3,C</em>4C<em>3, C</em>4 may be decreased during active disease due to consumption
    • Neutrophil recruitment and inflammation follow immune complex deposition

Type IV Hypersensitivity (Delayed-Type, T Cell–Mediated)

  • Definition and scope
    • Delayed-type hypersensitivity (DTH) reaction; no antibody involvement
    • Mediated primarily by T cells (CD4+ Th1/Th17 and CD8+ CTLs) and macrophages
  • Mechanism and timing
    • Antigen-presenting cells (APCs) present antigen to T cells, leading to T cell activation
    • Release of cytokines recruits macrophages and cytotoxic T cells
    • Inflammation and tissue damage occur as a delayed response
    • Onset is delayed: typically 48−72 hours48-72\text{ hours} after exposure
  • Key clinical examples
    • Contact dermatitis (e.g., poison ivy/toxic plants)
    • Tuberculin skin test (Mantoux) response
    • Some autoimmune conditions with T cell–mediated components (e.g., Type IV diabetes is a separate endocrine topic; not the focus here)
  • Features and signs
    • Localized inflammatory reaction at the site of antigen exposure
    • Pruritus, vesicles, erythema; rash begins at exposure site
    • Not mast cell/histamine driven; antihistamines are not effective
  • Diagnostic and management considerations
    • Identification of trigger and avoidance is central
    • Corticosteroids (e.g., prednisone, hydrocortisone) to suppress T cell–mediated inflammation
    • Avoidance of antihistamines for this mechanism; focus on anti-inflammatory and immunomodulatory therapy
  • Practical NP implications
    • Distinguish from Type I rashes by distribution and timing; local vs diffuse, immediate vs delayed
    • Use a pathophysiology-based approach to diagnosis and treatment planning
  • LaTeX-friendly notes
    • Delayed onset: t≈48−72 hourst \approx 48-72\ \text{hours} post-exposure
    • Mediators: T cells (CD4+, CD8+), macrophages; cytokine involvement; lack of circulating antibodies

Case Snippets and Interactive Scenarios (Integrated Review)

  • Case 1: 24-year-old woman with sneezing, runny nose, itchy eyes
    • Trigger: pollen or environmental allergens (dust mites, pet dander, etc.)
    • Pathophysiology: IgEIgE-mediated mast cell activation with histamine release
    • Treatment: antihistamines; allergen avoidance; consider nasal corticosteroids for nasal symptoms
  • Case 2: 10-year-old after strep throat with blood in urine and hypertension weeks later
    • Likely mechanism: immune complex deposition (Type III) in kidneys leading to glomerulonephritis
    • Management: blood pressure control, monitor kidney function; supportive care; avoid nephritic triggers
  • Case 3: Red, itchy rash with blisters on arms 48 hours after hiking
    • Likely mechanism: Type IV delayed hypersensitivity to plant exposure (e.g., poison ivy)
    • Treatment: topical steroids and localized care; avoid systemic antihistamines as histamine is not the primary mediator
  • Case 4: Newborn with jaundice and anemia shortly after birth
    • Likely mechanism: Type II cytotoxic reaction due to maternal antibodies against fetal red blood cells (e.g., Rh incompatibility)
    • Management: Rh immune globulin prophylaxis (RhoGAM) for Rh-negative mothers; supportive care for affected newborn
  • Quick diagnostic rationale cross-checks to prevent premature conclusions
    • Type I vs Type II vs Type III vs Type IV rely on mediator or site of injury, timing, and the presence of antibodies
    • Lupus example illustrates overlap: predominantly Type III with a Type II hematologic component

Diagnostic Tests and Practical Considerations (Summary Table-Style)

  • Type I
    • Tests: skin prick test, serum IgEIgE, specific IgE tests (e.g., RAST or ImmunoCAP)
  • Type II
    • Tests: Direct Coombs test (antibodies on RBCs), indirect Coombs test (free serum antibodies)
  • Type III
    • Tests: markers of systemic inflammation, organ-specific assessments; autoimmune panels for diseases like lupus (ANA, anti-dsDNA, anti-Smith), complement levels
  • Type IV
    • Tests: skin testing to identify delayed-type reactions; clinical assessment of exposure timing; patch testing in some cases

Therapeutic and Clinical Reasoning takeaways for Practice

  • Across all hypersensitivity types, inflammation is a central theme; anti-inflammatory strategies (especially corticosteroids) are commonly employed, with specific adjuncts per type
  • Avoid jumping to a single diagnosis; use a pathophysiology-based approach and consider multi-system involvement, especially in lupus (Type II and Type III overlap)
  • When medications are used, tailor to the mechanism (e.g., antihistamines for Type I, steroids for inflammatory/autoimmune processes, immunomodulators when needed)
  • Safety considerations in management
    • Anaphylaxis requires immediate epinephrine administration; educate patients on emergency plans and carrying an EpiPen
    • Blood transfusions in Type II (AIHA) require careful cross-matching due to autoantibodies; splenectomy or IVIG may be considered in refractory cases
    • Hyperthyroidism from Graves’ disease may require antithyroid drugs, beta blockers for symptomatic control, and potentially radioactive iodine or surgical options; monitor for exophthalmos and treat as needed
  • Interdisciplinary care and referral patterns
    • Complex autoimmune diseases often require nephrology, rheumatology, endocrinology, dermatology, and cardiology input depending on organ involvement
    • Pharmacology knowledge remains foundational to selecting appropriate therapies and anticipating adverse effects

Connections to Foundational Principles and Real-World Relevance

  • Foundational immunology concepts tied to clinical presentations
    • Antibody classes (IgE, IgG, IgM) and their effector functions drive each hypersensitivity type
    • Complement system and its role in mediating tissue injury via the classical pathway
    • Fc receptor–mediated cell interactions (e.g., FcγR on macrophages and NK cells)
  • Real-world relevance for NP practice
    • Differential diagnosis of rashes, anemia, hyperthyroidism, and autoimmune manifestations requires integrating immunology with organ-specific physiology
    • Management strategies emphasize patient education, safety, and chronic disease monitoring
  • Ethical and practical implications
    • Balancing immunosuppression with infection risk in autoimmune diseases
    • Shared decision-making about long-term therapies (e.g., immunosuppressants, biologics, and thyroid cancer risk with radioiodine)
    • Access to care and interdisciplinary coordination, especially for multi-system diseases like lupus

Quick Reference Table (Conceptual overview)

  • Type I: Mechanism = IgE + mast cells; Mediators = histamine, leukotrienes; Onset = rapid; Key examples = anaphylaxis, allergic rhinitis; Treatments = epinephrine (in severe cases), antihistamines, corticosteroids, avoidance, immunotherapy
  • Type II: Mechanism = antibodies against cell surface antigens; Mediators = complement (C1–C9), ADCC; Onset = hours–days; Key examples = AIHA, Graves’ disease; Tests = Coombs; Treatments = corticosteroids, immunosuppressants, IVIG, splenectomy (refractory)
  • Type III: Mechanism = immune complex deposition; Mediators = complement, neutrophils; Onset = variable; Key examples = SLE, PSGN; Treatments = NSAIDs, corticosteroids, immunosuppressants, antimalarials
  • Type IV: Mechanism = T cell–mediated, no antibodies; Mediators = cytokines, macrophages, CTLs; Onset = 48−72 hours48-72\ \text{hours}; Key examples = contact dermatitis, tuberculin skin test; Treatments = corticosteroids; Avoid antihistamines (not antibody-mediated)

Final thoughts for the exam

  • Be able to classify a clinical scenario into one of the four hypersensitivity types based on timing, mediator involvement, and site of pathology
  • Recognize overlap (e.g., lupus with type II hematologic involvement and type III systemic involvement) and justify the mechanism with pathophysiology
  • Remember the therapeutic rationale: treatment targets the underlying mechanism (e.g., suppressing antibody production, blocking mediator release, or dampening T-cell responses) and includes patient education and safety planning